FF
ABBV icon

Formulate Financial’s AbbVie ABBV Stock Holding History

Formulate Financial’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$324K Hold
1,287
– – 0.34% 21
2026
Q1 		$280K Hold
1,287
– – 0.35% 20
2025
Q4 		$294K Buy
1,287
+8
+0.6% +$1.82K 0.34% 23
2025
Q3 		$296K Buy
+1,279
New +$260K 0.37% 20

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Formulate Financial's ABBV Position: Q2 2026 in Review

Formulate Financial held its AbbVie (ABBV) position steady in Q2 2026 at 1,287 shares worth $324K. The position accounts for 0.34% of the portfolio, ranked #21.

Formulate Financial first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 2,841 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Formulate Financial held 1,287 shares of AbbVie worth $324K as of Q2 2026.
  • Formulate Financial left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.34% of Formulate Financial's portfolio in Q2 2026, its #21 holding.
  • Formulate Financial first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
  • 2,841 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Formulate Financial's 13F filing for Q2 2026, filed 31 Jul 2026.